Seeking Alpha

Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy

WALTHAM, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company and leader in complement, today announced that the company has received ...
Ophthalmology Times

FDA grants Fast Track Designation to Complement Therapeutics’ CTx001 for geographic atrophy

The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...
Healio

Should I Treat This Patient With Geographic Atrophy? Weighing Benefits and Burden of Treatment With Complement Inhibitors

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Recent advances in imaging and the approval of ...
Hosted on MSN

Apellis Post Hoc Analysis Confirms Long-Term Benefit of SYFOVRE for Geographic Atrophy

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the best upside stocks to buy now. On November 12, Apellis Pharmaceuticals announced that a post hoc analysis of the Phase 3 GALE extension study ...
Seeking Alpha

Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy

Dec. 16, 2022 7:00 AM ETApellis Pharmaceuticals, Inc. (APLS) WALTHAM, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company and leader in ...
FiercePharma

Apellis' weak quarter for Syfovre signals uphill climb for geographic atrophy med: analyst

Despite holding the lead with its complement inhibitor Syfovre, Apellis Pharmaceuticals is discovering that the geographic atrophy market is a tough nut to crack. Syfovre—which became the first ...